First medicine targeting BRCA mutations to show clinical benefit in adjuvant settingWILMINGTON, Del. (BUSINESS WIRE) AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced results from the OlympiA Phase III trial showed LYNPARZA® (olaparib) demonstrated a statistically significa.
Subscription Notification
We have noticed that there is an issue with your subscription billing details. Please update your billing details here
Please update your billing information
The subscription details associated with this account need to be updated. Please update your billing details here to continue enjoying your subscription.
Your subscription will end shortly
Please update your billing details here to continue enjoying your access to the most informative and considered journalism in the UK.
Benefit Also in Early Stage: Olaparib in BRCA+ Breast Cancer medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
A “search and destroy” prostate cancer drug that seeks out tumours and delivers a precisely targeted dose of radiation can keep men with advanced disease alive for longer, a study has shown.The